View as an RSS Feed
PRO articles cover stocks that fly under most investors' radar screens.
Evaluating Sucampo's Upside Potential
- Sucampo has solid fundamentals, science and partnerships.
- Revenue is projected to grow by ~20% in the next 2 years.
- Sucampo has upside potential.
Exact Sciences Is A Near-Term Short Due To Risks And Assumptions About Its Future Business
- Exact Sciences is currently overvalued with the assumption of PMA approval.
- The assumed $300 premium pricing by CMS and future sales figures are far from certain.
- With both near term risks and assumptions, EXAS is a near-term short.
The Long-Term Risks About Ocera Therapeutics
- Hepatic Encephalopathy market is competitive.
- Ocera has yet to show a convincing advantage over other alternatives.
- Ocera's OCR002 molecule faces a fundamental risk.
Analysis Of The Near-Term Value Drivers Of Spectrum Pharmaceuticals
- Analysis of the 6 key value drivers of SPPI.
- Revenue growth of Fusilev, Marqibo and Fotolyn are key.
- Over 50% CAGR for revenue possible if SPPI can fully leverage these value drivers.
- Analysis Of Intercept Pharmaceuticals And OCA's Future Potential